A detailed history of Apollon Wealth Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Apollon Wealth Management, LLC holds 8,196 shares of VRTX stock, worth $4.12 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
8,196
Previous 7,403 10.71%
Holding current value
$4.12 Million
Previous $3.47 Million 9.86%
% of portfolio
0.11%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$460.0 - $505.78 $364,780 - $401,083
793 Added 10.71%
8,196 $3.81 Million
Q2 2024

Jul 19, 2024

BUY
$392.81 - $485.53 $122,949 - $151,970
313 Added 4.41%
7,403 $3.47 Million
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $297,613 - $325,638
730 Added 11.48%
7,090 $2.96 Million
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $492,205 - $589,325
1,435 Added 29.14%
6,360 $2.59 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $127,832 - $137,009
378 Added 8.31%
4,925 $1.71 Million
Q2 2023

Aug 04, 2023

BUY
$314.42 - $351.91 $36,472 - $40,821
116 Added 2.62%
4,547 $1.6 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $65,426 - $74,636
-231 Reduced 4.95%
4,431 $1.4 Million
Q4 2022

Feb 15, 2023

BUY
$285.76 - $321.48 $203,175 - $228,572
711 Added 18.0%
4,662 $1.35 Million
Q3 2022

Nov 08, 2022

BUY
$273.83 - $305.53 $163,750 - $182,706
598 Added 17.83%
3,951 $1.14 Million
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $83,880 - $104,440
357 Added 11.92%
3,353 $945,000
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $122,002 - $143,794
551 Added 22.54%
2,996 $782,000
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $432,789 - $546,335
2,445 New
2,445 $537,000
Q3 2020

Nov 03, 2020

SELL
$255.65 - $303.1 $4,090 - $4,849
-16 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $3,607 - $4,732
16 New
16 $5,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Apollon Wealth Management, LLC Portfolio

Follow Apollon Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Apollon Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Apollon Wealth Management, LLC with notifications on news.